Jun 2026 (Q2 FY26) — Aug 6, 2026
Tucows Q2 FY26 — Ting's First Positive Adjusted EBITDA Quarter, Balance Sheet Streamlined
Read the full callTucows (TCX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Tucows earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 101 | +2.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -5.4 | −2.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -20.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$9.36 −7.96% · −$0.81
Performance −48.4% 1Y
1Y: $18.15 on 17 Oct 2025 → $9.36. High $24.9 (14 Jan 2026), low $8.48 (12 Oct 2026).
- Previous close
- $10.17
- 52-week range
- $8.48 – $24.9
- One year
- −48.82%
Overview
- Symbol
- TCX
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Tucows earnings calls (TCX)
Financials
What the filings say
Net profit, year on year: −31% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 92 | 93 | 95 | 98 | 99 | 99 | 97 | 101 |
| Operating profit | -10 | -30 | -2 | -3 | -10 | -9 | -4 | -5 |
| Operating margin | −10.9% | −32.1% | −2.1% | −2.9% | −9.7% | −9.1% | −4.5% | −5.4% |
| Other income | -9 | -11 | -11 | -10 | -11 | -11 | -11 | -12 |
| Interest | 14 | 15 | 14 | 14 | 14 | 15 | 14 | 15 |
| Profit before tax | -19 | -41 | -13 | -13 | -21 | -20 | -16 | -17 |
| Tax rate | −16.0% | −4.7% | −16.7% | −16.9% | −11.9% | −8.0% | −15.2% | −18.1% |
| Net profit | -22 | -42 | -15 | -16 | -23 | -22 | -18 | -20 |
| EPS ($ per share) | -2.03 | — | -1.37 | -1.41 | -2.08 | — | -1.63 | -1.84 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 17 | 21 | 29 | 32 | 34 | 37 | 38 |
| Reserves | 61 | 76 | 80 | 83 | 56 | -40 | -150 | -226 |
| Total liabilities | 260 | 332 | 347 | 425 | 568 | 789 | 854 | 895 |
| Fixed assets | 48 | 82 | 118 | 173 | 281 | 340 | 331 | 282 |
| Total assets | 340 | 426 | 452 | 540 | 665 | 798 | 759 | 731 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 37 | 40 | 36 | 30 | 20 | -5 | -20 | -6 |
| Cash from investing | -30 | -76 | -53 | -102 | -137 | -93 | -56 | 2 |
| Cash from financing | -13 | 43 | 5 | 73 | 132 | 179 | 44 | -5 |
| Net cash flow | -5 | 8 | -12 | 1 | 14 | 81 | -32 | -9 |
| Capital expenditure | -28 | -44 | -44 | -73 | -137 | -92 | -56 | -17 |
| Free cash flow | 9 | -4 | -8 | -44 | -117 | -97 | -76 | -23 |
Insider filings
1 filing, all on Dec 24, 2025.
Open market
decisions to buy or sellNobody bought or sold TCX on the open market in this window. The filing below is 1 gift.
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Dec 24, 2025 | NOSS ELLIOT Director | Gift | 20,250 | $0 |
| Jul 17, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $11.3K |
| Jul 11, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 700 | $16.0K |
| Jul 10, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 400 | $9.0K |
| Jul 10, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,600 | $34.8K |
| Jul 9, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $10.6K |
| Jul 8, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,500 | $52.0K |
| Jul 7, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,600 | $53.3K |
| Jul 2, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 3,200 | $65.4K |
| May 9, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 100 | $1.8K |
| May 8, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,600 | $27.7K |
| May 7, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 700 | $11.5K |
| May 6, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 700 | $11.4K |
| May 5, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 800 | $13.0K |
| Apr 24, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $8.5K |
| Apr 23, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $8.3K |
| Apr 22, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $8.2K |
| Apr 17, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $16.2K |
| Apr 14, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $16.2K |
| Apr 11, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $15.6K |
| Apr 9, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 300 | $4.5K |
| Apr 7, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $7.7K |
| Apr 4, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $16.2K |
| Apr 3, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $16.6K |
| Apr 2, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 200 | $3.4K |
| Feb 14, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,260 | $23.9K |
| Feb 14, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $31.9K |
| Feb 14, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,500 | $42.1K |
| Feb 14, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $36.0K |
| Feb 6, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $7.9K |
| Feb 5, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 300 | $4.7K |
| Feb 4, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $7.8K |
| Jan 27, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 100 | $1.7K |
| Jan 24, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $33.8K |
| Jan 23, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $8.2K |
| Jan 22, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $32.4K |
| Jan 15, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 200 | $3.3K |
| Jan 13, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 100 | $1.6K |
| Jan 8, 2025 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,100 | $18.5K |
| Oct 18, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $9.8K |
| Oct 17, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,500 | $28.5K |
| Oct 15, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $19.6K |
| Oct 14, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 500 | $9.8K |
| Oct 11, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 3,000 | $57.7K |
| Oct 10, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $37.7K |
| Oct 9, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $19.3K |
| Oct 8, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 200 | $3.9K |
| Oct 7, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 100 | $2.0K |
| Oct 4, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,600 | $31.9K |
| Oct 2, 2024 | NOSS ELLIOT Chief Executive Officer | Sale 10b5-1 plan | 1,700 | $34.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TUCOWS INC /PA/
Free account. Everything above stays public.
Write why you follow TUCOWS INC /PA/ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading